Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Dopamine therapy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    117 result(s) found for: Dopamine therapy. Displaying page 5 of 6.
    « Previous 1  2  3  4  5  6  Next»
    EudraCT Number: 2020-003942-35 Sponsor Protocol Number: APHP200018 Start Date*: 2021-04-27
    Sponsor Name:Assistance Publique - Hôpitaux Paris
    Full Title: HydrOcortisone and fludRocortisoNe for critical ILLness-related corticosteroid insufficiency
    Medical condition: Critically ill patients with a SOFA score (SOFA; Sequential Organ Failure Assessment) ≥ 6, for at least 6 consecutive hours, suffering from CIRCI, to the notable exception of patients with septic s...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10018065 - General disorders and administration site conditions 10077264 Critical illness PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-003961-25 Sponsor Protocol Number: TOZ-CL06 Start Date*: 2017-06-30
    Sponsor Name:Biotie Therapies
    Full Title: A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients with Parkinson’s Disease Experiencing End of Dose “Wearing-Off”
    Medical condition: Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004852 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) HU (Prematurely Ended) ES (Prematurely Ended) CZ (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-006291-38 Sponsor Protocol Number: 06-010 Start Date*: 2007-10-02
    Sponsor Name:Jazz Pharmaceuticals, Inc.
    Full Title: A Long-Term, Open-Label Safety and Efficacy Study of Xyrem (sodium oxybate) in Subjects with Fibromyalgia
    Medical condition: Fibromyalgia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10048439 Fibromyalgia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) FR (Ongoing) NL (Completed) PL (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-004447-11 Sponsor Protocol Number: VR040/2/008 Start Date*: Information not available in EudraCT
    Sponsor Name:Vectura Limited
    Full Title: A Phase IIb Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study Investigating the Efficacy and Safety of Apomorphine Inhalation Powder in Patients With “On-Off” or “Wearing-Off” Effe...
    Medical condition: Unpredictable motor fluctuation or “On-Off” or “Wearing-Off” Effects Fluctuating associated with Idiopathic Parkinson’s Disease
    Disease: Version SOC Term Classification Code Term Level
    11 10067209 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-000135-14 Sponsor Protocol Number: PXT-CL17-001 Start Date*: 2017-05-26
    Sponsor Name:Prexton Therapeutics B.V.
    Full Title: A Multi-centre, Double-blind, Randomised, Placebo-controlled, Parallel-arm Phase IIa Trial to Evaluate the Efficacy, Safety and Tolerability of 28-Day Oral Treatment with PXT002331 (foliglurax) in ...
    Medical condition: Parkinson’s Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) GB (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-017238-39 Sponsor Protocol Number: IPX066-B09-06 Start Date*: 2010-09-15
    Sponsor Name:Impax Laboratories, Inc., acting through its Impax Pharmaceuticals Division (Impax)
    Full Title: A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) in Advanced Parkinson’s Disease
    Medical condition: Idiopathic Parkinson’s Disease (paralysis agitans)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10061536 Parkinson's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) IT (Completed) BE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-001420-34 Sponsor Protocol Number: 0001 Start Date*: 2020-04-14
    Sponsor Name:Aarhus University
    Full Title: Senicapoc in COVID-19 Patients with Severe Respiratory Insufficiency – A Randomized, Open-Label, Phase II Trial
    Medical condition: Infection with COVID19
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001052 Acute respiratory distress syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-003923-40 Sponsor Protocol Number: APHP200019 Start Date*: 2021-01-08
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS ( AP-HP)
    Full Title: A Multicentre Concealed‐Allocation Parallel‐Group Blinded Randomized Controlled Trial to Ascertain the Effect of High‐Dose Intravenous Vitamin C Compared to Placebo on Mortality or Persistent Organ...
    Medical condition: Sepsis complicated by ARDS
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001052 Acute respiratory distress syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-002112-99 Sponsor Protocol Number: F1K-MC-EVDK Start Date*: 2006-09-26
    Sponsor Name:Eli Lilly & Company Limited
    Full Title: A Phase 2 Study to Evaluate Dose and Duration of Treatment of Drotrecogin Alfa (Activated) Using Serial Measurements of Protein C in Patients with Severe Sepsis and Multiple Organ Dysfunction
    Medical condition: severe sepsis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10040047 Sepsis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) SE (Prematurely Ended) FR (Completed) FI (Completed) IT (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-020112-11 Sponsor Protocol Number: P07037 Start Date*: 2011-06-29
    Sponsor Name:Schering-Plough Research Institute, a division of Schering Corporation
    Full Title: A Phase 3, 12-Week, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Preladenant in Subjects with Moderate to Severe Parkinson’s Disease. (Phase 3; Protocol No. P07037)
    Medical condition: Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2013-005118-36 Sponsor Protocol Number: NOH401 Start Date*: 2014-06-30
    Sponsor Name:Chelsea Therapeutics, Incorporated
    Full Title: A clinical study of Patients with symptomatic neurogenic orthostatic HypOtENsion to assess sustaIned effects of droXidopa therapy
    Medical condition: Symptomatic neurogenic orthostatic hypotension
    Disease: Version SOC Term Classification Code Term Level
    17.0 10047065 - Vascular disorders 10031127 Orthostatic hypotension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-001657-42 Sponsor Protocol Number: AKST4290-211 Start Date*: 2019-10-22
    Sponsor Name:Alkahest, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AKST4290 in Subjects with Parkinson's Disease on Stable Dopaminergic Treatment
    Medical condition: Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2006-002937-20 Sponsor Protocol Number: E2007-G000-309 Start Date*: 2006-12-11
    Sponsor Name:Eisai Limited
    Full Title: A Multi-centre, Randomised, Double-blind, Placebo- and Entacapone-controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients...
    Medical condition: Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Prematurely Ended) CZ (Prematurely Ended) LV (Prematurely Ended) LT (Prematurely Ended) IT (Completed) FR (Completed) ES (Completed) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-005054-59 Sponsor Protocol Number: SYN115-CL02 Start Date*: 2012-02-21
    Sponsor Name:Biotie Therapies Inc.
    Full Title: A double-blind, randomized, placebo-controlled study of the safety and efficacy of SYN115 as adjunctive therapy in levodopa-treated Parkinson’s subjects with end of dose wearing off
    Medical condition: Parkinson’s disease
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004852 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: RO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000262-30 Sponsor Protocol Number: EXN-32-CD-002 Start Date*: 2017-07-10
    Sponsor Name:DR. REDDY’S LABORATORIES LIMITED
    Full Title: Efficacy, Safety, Tolerability and Pharmacokinetics of EXN-32 and EXN-44 in patients with Parkinson¿s Disease experiencing motor fluctuations
    Medical condition: Parkinson's Desease (PD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-021018-49 Sponsor Protocol Number: FOILED Start Date*: 2012-05-25
    Sponsor Name:GWT-TUD GmbH
    Full Title: Fish OIL optimal dosE Determination Study
    Medical condition: Mechanically ventilated adult patients (>18 years old) admitted to ICU with clinical evidence of sepsis, sepsis associated organ dysfunction, and high expression of inflammatory cytokines.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10040070 Septic shock PT
    14.1 10021881 - Infections and infestations 10040047 Sepsis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-003799-22 Sponsor Protocol Number: CVT-301-005 Start Date*: 2015-02-11
    Sponsor Name:Civitas Therapeutics, Inc.
    Full Title: A Phase 3, Randomized Study Investigating the Safety of CVT-301 (Levodopa Inhalation Powder) in Parkinson’s Disease Patients With Motor Response Fluctuations (OFF Phenomena) Compared to an Obser...
    Medical condition: Parkinson's Disease With Motor Response Fluctuations (OFF Phenomena)
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004852 10034007 Parkinson's disease NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) GB (Completed) CZ (Completed) DE (Completed) ES (Completed) BE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2014-002600-24 Sponsor Protocol Number: Z7219L02 Start Date*: 2015-11-03
    Sponsor Name:Zambon S.P.A.
    Full Title: A TWO YEAR, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF SAFINAMIDE 100 MG, ONCE DAILY, AS ADD ON THERAPY, IN IDIOPATHIC PARKINSO...
    Medical condition: Idiopathic Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Prematurely Ended) AT (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000778-46 Sponsor Protocol Number: LiBiDi-EK314/11 Start Date*: 2013-01-17
    Sponsor Name:Forschungszentrum Jülich GmbH
    Full Title: Elucidation of Lithium Working Mechanism in Bipolar Disorder by means of Multi Modal Brain Imaging (LiBiDi)
    Medical condition: Healthy volunteers Bipolar patients type 1
    Disease: Version SOC Term Classification Code Term Level
    14.1 10018065 - General disorders and administration site conditions 10043890 Tiredness LLT
    14.1 10017947 - Gastrointestinal disorders 10028821 Nausea with vomiting LLT
    14.1 10029205 - Nervous system disorders 10013575 Dizziness and giddiness LLT
    14.1 10029205 - Nervous system disorders 10051385 Drug-induced headache LLT
    14.1 10018065 - General disorders and administration site conditions 10021689 Increased thirst LLT
    14.1 10027433 - Metabolism and nutrition disorders 10036164 Poor weight gain LLT
    14.1 10029205 - Nervous system disorders 10044577 Tremor of hands LLT
    14.1 10029205 - Nervous system disorders 10027176 Memory loss LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-014688-37 Sponsor Protocol Number: IPX066-B09-02 Start Date*: 2009-12-15
    Sponsor Name:Impax Laboratories, Inc.
    Full Title: A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson’s Disease
    Medical condition: Advanced Parkinson’s Disease subjects with motor fluctuations
    Disease: Version SOC Term Classification Code Term Level
    12.0 10061536 Parkinson's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) ES (Completed) PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 16 16:38:47 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA